Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
MYOV Myovant Sciences
26.9000.0000.00%
Trading Session
01/27 12:58 ET
High
26.900
Open
26.880
Turnover
8.21M
Low
26.880
Pre Close
26.900
Volume
305.08K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Myovant Sciences (MYOV) Reports Q3 Loss, Lags Revenue Estimates
Myovant Sciences GAAP EPS of -$0.56 Beats by $0.08, Revenue of $100.23M Misses by $2.13M
Myovant Sciences Q3 Sales $100.20M Miss $102.36M Estimate
Myovant Sciences (NYSE:MYOV) reported quarterly sales of $100.20 million which missed the analyst consensus estimate of $102.36 million by 2.11 percent. This is a 7.17K percent increase over sales of
Myovant Sciences Reports Q3 EPS (59c), Consensus (47c)
Myovant Sciences 3Q Rev $100.2M >MYOV
Press Release: Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022
Myovant Sciences Announces Corporate Updates and Financial Results for Third Fiscal Quarter 2022 -- Third fiscal quarter 2022 total revenue of $100.2 million; including net product revenue
Earnings Flash (MYOV) MYOVANT SCIENCES Reports Q3 Revenue $100.2M
04:06 PM EST, 01/26/2023 (MT Newswires) -- Earnings Flash (MYOV) MYOVANT SCIENCES Reports Q3 Revenue $100.2M
Myovant Sciences 3Q Loss/Shr 59c >MYOV
Myovant Sciences 3Q Loss/Shr 59c >MYOV
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAFE, LBAI, FCRD, MYOV
NEW YORK, Jan. 26, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties
MYOVANT SCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Myovant Sciences - MYOV
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of Myovant Sciences
Company Overview
More
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.
CEO： Mr. David C. Marek
Market： NYSE
Listing Date： 10/27/2016
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet